{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T20:22:45Z","timestamp":1648930965001},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr HIV\/AIDS Rep"],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1007\/s11904-007-0021-x","type":"journal-article","created":{"date-parts":[[2007,8,17]],"date-time":"2007-08-17T16:32:20Z","timestamp":1187368340000},"page":"141-146","source":"Crossref","is-referenced-by-count":3,"title":["Preventing bacterial disease in the HIV-infected of sub-saharan africa: The role of cotrimoxazole and the pneumococcal vaccines"],"prefix":"10.1007","volume":"4","author":[{"given":"David C.","family":"Spencer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,8,18]]},"reference":[{"key":"21_CR1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/00002030-200501280-00012","volume":"19","author":"P. Groenewald","year":"2005","unstructured":"Groenewald P, Nannan N, Bourne D, et al.: Identifying deaths from AIDS in South Africa. AIDS 2005, 19:193\u2013201.","journal-title":"AIDS"},{"key":"21_CR2","first-page":"3","volume-title":"National Antiretroviral Treatment Guidelines for South Africa. National Department of Health","author":"N.P. Simelela","year":"2004","unstructured":"Simelela NP: National Antiretroviral Treatment Guidelines for South Africa. National Department of Health. Pretoria, South Africa: Jacana; 2004:3."},{"key":"21_CR3","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/S0140-6736(06)69117-4","volume":"368","author":"M. Badri","year":"2006","unstructured":"Badri M, Lawn SD, Wood R: Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: a longitudinal study. Lancet 2006, 368:1254\u20131259","journal-title":"Lancet"},{"key":"21_CR4","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1086\/339540","volume":"34","author":"E.L. Corbett","year":"2002","unstructured":"Corbett EL, Churchyard GJ, Charalambos S, et al.: Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus. Clin Infect Dis 2002, 34:1251\u20131258.","journal-title":"Clin Infect Dis"},{"key":"21_CR5","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0140-6736(02)11082-8","volume":"360","author":"C. Chintu","year":"2002","unstructured":"Chintu C, Mudenda V, Lucas S, et al.: Lung diseases at necropsy in African children dying from respiratory illnesses: a descriptive necropsy study. Lancet 2002, 360:985\u2013990.","journal-title":"Lancet"},{"key":"21_CR6","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/01.qai.0000221679.14445.1b","volume":"42","author":"C. Watera","year":"2006","unstructured":"Watera C, Todd J, Muwonge R, et al.: Feasibility and effectiveness of cotrimoxazole prophylaxis for HIV-1-infected adults attending an HIV\/AIDS clinic in Uganda. J Acquir Immune Defic Syndr 2006, 42:373\u2013378.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"21_CR7","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1097\/00002030-200011100-00036","volume":"14","author":"X. Anglaret","year":"2000","unstructured":"Anglaret X, Toure S, Ouassa T, et al.: Thresholds of CD4 cells for initiating trimethoprim-sulfamethoxazole prophylaxis in west Africa [research letter]. AIDS 2000, 14:2628\u20132629.","journal-title":"AIDS"},{"key":"21_CR8","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0140-6736(07)60195-0","volume":"369","author":"A. Sinha","year":"2007","unstructured":"Sinha A, Levine O, Knoll MD, Lieu TA: Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis. Lancet 2007, 369:389\u2013396.","journal-title":"Lancet"},{"key":"21_CR9","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/S0140-6736(06)69637-2","volume":"368","author":"C.G. Whitney","year":"2006","unstructured":"Whitney CG, Pilishvili T, Farley MM, et al.: Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006, 368:1495\u20131502.","journal-title":"Lancet"},{"key":"21_CR10","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1086\/320532","volume":"32","author":"P. Huovinen","year":"2001","unstructured":"Huovinen P: Resistance to trimethoprim-sulfamethoxazole. Clin Infect Dis 2001, 32:1608\u20131614.","journal-title":"Clin Infect Dis"},{"key":"21_CR11","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1001\/archinte.163.4.402","volume":"163","author":"P.A. Masters","year":"2003","unstructured":"Masters PA, O\u2019Bryan TA, Zurlo J, et al.: Trimethoprim-sulfamethoxazole revisited. Arch Intern Med 2003, 163:402\u2013410.","journal-title":"Arch Intern Med"},{"key":"21_CR12","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(03)12951-0","volume":"361","author":"C. Roper","year":"2003","unstructured":"Roper C, Pearce R, Bredenkamp B, et al.: Antifolate antimalarial resistance in southeast Africa: a population-based analysis. Lancet 2003, 361:1174\u20131181.","journal-title":"Lancet"},{"key":"21_CR13","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1086\/315382","volume":"181","author":"D.R. Feikin","year":"2000","unstructured":"Feikin DR, Dowell SF, Nwanyanwu OC, et al.: Increased carriage of trimethoprim-supfamethoxazole resistant Streptococcus pneumoniae in Malawian children after treatment with sulfadoxine-pyrimethamine. J Infect Dis 2000, 181:1501\u20131505.","journal-title":"J Infect Dis"},{"key":"21_CR14","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1086\/315148","volume":"180","author":"L. Ma","year":"1999","unstructured":"Ma L, Borio L, Masur H, Kovacs JA: Pneumocystis carinii dihydropteroate synthase but not dihydrofolate reductase gene mutations correlate with prior trimethoprimsulfamethoxazole or daspone use. J Infect Dis 1999, 180:1969\u20131978.","journal-title":"J Infect Dis"},{"key":"21_CR15","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/00002030-200201040-00013","volume":"16","author":"D.D. Ruffini","year":"2002","unstructured":"Ruffini DD, Madhi SA: The high burden of Pneumocystis carinii pneumonia in Africa HIV-1-infected children hospitalized for severe pneumonia. AIDS 2002, 16:105\u2013112.","journal-title":"AIDS"},{"key":"21_CR16","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/S0140-6736(98)07399-1","volume":"353","author":"X. Anglaret","year":"1999","unstructured":"Anglaret X, Chene G, Attia A, et al.: Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Cote d\u2019Ivoire: a randomized trial. Lancet 1999, 353:1463\u20131468.","journal-title":"Lancet"},{"key":"21_CR17","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/S0140-6736(99)03465-0","volume":"353","author":"S.Z. Wiktor","year":"1999","unstructured":"Wiktor SZ, Sassan-Morokro M, Grant AD, et al.: Efficacy of trimethoprim-sulfamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abijan, Cote d\u2019Ivoire: a randomized controlled trial. Lancet 1999, 353:1469\u20131475.","journal-title":"Lancet"},{"key":"21_CR18","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/S0140-6736(04)17225-5","volume":"364","author":"J. Mermin","year":"2004","unstructured":"Mermin J, Lule J, Ekwaru JP, et al.: Effect of co-trimoxazole prophylaxis, morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 2004, 364:1428\u20131434.","journal-title":"Lancet"},{"key":"21_CR19","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1097\/01.aids.0000174449.32756.c7","volume":"19","author":"J. Mermin","year":"2005","unstructured":"Mermin J, Lule J, Ekwaru JP, et al.: Cotrimoxazole prophylaxis by HIV-infected persons in Uganda reduces morbidity and mortality among HIV-uninfected family members. AIDS 2005, 19:1035\u20131042.","journal-title":"AIDS"},{"key":"21_CR20","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0140-6736(06)68541-3","volume":"367","author":"J. Mermin","year":"2006","unstructured":"Mermin J, Ekwaru JP, Liechty CA, et al.: Effect of cotrimoxazole, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study. Lancet 2006, 367:1256\u20131261.","journal-title":"Lancet"},{"key":"21_CR21","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1097\/01.aids.0000168986.12832.a4","volume":"19","author":"J. Mermin","year":"2005","unstructured":"Mermin J, Lule JR, Ekwaru JP, Pitter C: Should cotrimoxaozle prophylaxis be taken by all adults with HIV in Africa? AIDS 2005, 19:845\u2013846.","journal-title":"AIDS"},{"key":"21_CR22","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/S0140-6736(04)17442-4","volume":"364","author":"C. Chintu","year":"2004","unstructured":"Chintu C, Bhat GJ, Walker AS, et al.: Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomized placebo-controlled trial. Lancet 2004, 364: 1865\u20131871.","journal-title":"Lancet"},{"key":"21_CR23","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1086\/344951","volume":"36","author":"D.T. Fisk","year":"2003","unstructured":"Fisk DT, Mesnick S, Kazazjian PH: Pneumocystic carinii pneumonia in patients in the developing world who have acquired immunodeficiency syndrome. Clin Infect Dis 2003, 36:70\u201378.","journal-title":"Clin Infect Dis"},{"key":"21_CR24","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1086\/343049","volume":"35","author":"S.A. Madhi","year":"2002","unstructured":"Madhi SA, Cutland C, Ismail K, et al.: Ineffectiveness of trimethoprim-sulfamethoxazole prophylax is and the importance of bacterial and viral coinfections in African children with Pneumocystis carinii pneumonia. Clin Infect Dis 2002, 35:1120\u20131126.","journal-title":"Clin Infect Dis"},{"key":"21_CR25","unstructured":"Walter J, Mwiya M, Scott N, et al.: Cotrimoxazole prophylaxis and adverse birth outcomes among HIV-infected women in Lusaka, Zambia [abstract 126]. Paper presented at the 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO; February 5\u20138, 2006."},{"key":"21_CR26","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00002030-200501280-00008","volume":"19","author":"K. Grimwade","year":"2005","unstructured":"Grimwade K, Sturm AW, Nunn AJ, et al.: Effestiveness of cotrimoxazole prophylaxis on mortality in adults with tuberculosis in rural South Africa. AIDS 2005, 19:163\u2013168.","journal-title":"AIDS"},{"key":"21_CR27","unstructured":"World Health Organization: WHO expert consultation on cotrimoxazole prophylaxis in HIV infection, http:\/\/www.who.int\/hiv\/pub\/meetingreports\/ctxprophylaxismeeting.pdf . Accessed May 4, 2007."},{"key":"21_CR28","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S0140-6736(01)06227-4","volume":"358","author":"X. Anglaret","year":"2001","unstructured":"Anglaret X: Trimethoprim-sulfamethoxazole prophylaxis in sub-Saharan Africa. Lancet 2001, 358:1027\u20131028.","journal-title":"Lancet"},{"key":"21_CR29","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/j.1365-3156.2005.01488.x","volume":"10","author":"J. Mermin","year":"2005","unstructured":"Mermin J, Bunnell R, Lule J, et al.: Developing an evidence-based preventive care package for persons with HIV in Africa. Trop Med Internat Health 2005, 10:961\u2013970.","journal-title":"Trop Med Internat Health"},{"key":"21_CR30","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1016\/S0140-6736(02)09095-5","volume":"359","author":"E.L. Corbett","year":"2002","unstructured":"Corbett EL, Steketee RW, ter Kuile FO, et al.: HIV\/AIDS and the control of other infectious diseases in Africa. Lancet 2002, 359:2177\u20132187.","journal-title":"Lancet"},{"key":"21_CR31","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1086\/420933","volume":"38","author":"Q. Jordano","year":"2004","unstructured":"Jordano Q, Falco V, Almrante B, et al.: Invasive pneumococcal disease in patients in fected with HIV: still a threat in the era of highly active antiretroviral therapy. Clin Infect Dis 2004, 38:1623\u20131628.","journal-title":"Clin Infect Dis"},{"key":"21_CR32","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1086\/321901","volume":"33","author":"M.S. Dworkin","year":"2001","unstructured":"Dworkin MS, Williamson J, Jones JL, et al.: Prophylaxis with trimethoprim-sulfamethoxazole for human immunodeficiency virus-infected patients: impact on risk for infectious diseases. Clin Infect Dis 2001, 33:393\u2013398.","journal-title":"Clin Infect Dis"},{"key":"21_CR33","doi-asserted-by":"crossref","unstructured":"Watera C, Nakiyingi J, Miiro G, et al.: 23-Valent pneumococal polysaccharide vaccine in HIV-infected Ugandan adults: 6-year follow-up of a clinical trial cohort. AIDS2004, 18:1210\u20131213.","DOI":"10.1097\/00002030-200405210-00018"},{"key":"21_CR34","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1097\/00002030-200207050-00013","volume":"16","author":"S.B. Gordon","year":"2002","unstructured":"Gordon SB, Chaponda M, Walsh AL, et al.: Pneumococcal disease in HIV-infected Malawian adults: acute mortality and long-tern survival. AIDS 2002, 16:1409\u20131417.","journal-title":"AIDS"},{"key":"21_CR35","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1086\/506941","volume":"43","author":"P.C. Hill","year":"2006","unstructured":"Hill PC, Akisanya A, Sankareh K, et al.: Nasopharyngeal Carriage of Streptococcus pneumoniae in Gambian Villagers. Clin Infect Dis 2006, 43:673\u2013679.","journal-title":"Clin Infect Dis"},{"key":"21_CR36","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJMoa035060","volume":"349","author":"K.P. Klugman","year":"2003","unstructured":"Klugman KP, Madhi SA, Huebner RE, et al.: A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003, 349:1314\u20131318.","journal-title":"N Engl J Med"},{"key":"21_CR37","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/S0140-6736(05)71876-6","volume":"365","author":"F.T. Cutts","year":"2005","unstructured":"Cutts FT, Zaman SMA, Enwere G, et al.: Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in the Gambia: randomized, double-blind, placebo-controlled trial. Lancet 2005, 365:1139\u20131146.","journal-title":"Lancet"},{"key":"21_CR38","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1086\/429828","volume":"40","author":"S.A. Madhi","year":"2005","unstructured":"Madhi SA, Kuwanda L, Cutland C, Klugman KP: The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and uninfected children. Clin Infect Dis 2005, 40:1511\u20131518.","journal-title":"Clin Infect Dis"},{"key":"21_CR39","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/S0140-6736(06)68703-5","volume":"367","author":"O.S. Levine","year":"2006","unstructured":"Levine OS, O\u2019Brien KL, Knoll M, et al.: Pneumococcal vaccination in developing countries. Lancet 2006, 367:1880\u20131882.","journal-title":"Lancet"},{"key":"21_CR40","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1086\/322676","volume":"33","author":"C.G. Whitney","year":"2001","unstructured":"Whitney CG, Schaffner W, Butler JC: Rethinking recommendations for use of pneumococcal vaccines in adults. Clin Infect Dis 2001, 33:662\u2013675.","journal-title":"Clin Infect Dis"},{"key":"21_CR41","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1086\/319218","volume":"32","author":"M.S. Dworkin","year":"2001","unstructured":"Dworkin MS, Ward JW, Hanson DL, et al.: Pneumococcal disease among the human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination. Clin Infect Dis 2001, 32:794\u2013800.","journal-title":"Clin Infect Dis"},{"key":"21_CR42","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S0140-6736(96)90076-8","volume":"347","author":"C.F. Gilks","year":"1996","unstructured":"Gilks CF, Ojoo SA, Ojoo JC, et al.: Invasive pneumococcal disease in a cohort of predominantly HIV-1 infected female sex workers in Nairobi, Kenya. Lancet 1996, 347:718\u2013723.","journal-title":"Lancet"},{"key":"21_CR43","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(00)02377-1","volume":"355","author":"N. French","year":"2000","unstructured":"French N, Nakiyingi J, Carpenter LM, et al.: 23-valent pneumococcal polysaccharide vaccine in HIV-1 infected Ugandan adults: double-blind, randomized and placebocontrolled trial. Lancet 2000, 355:2106\u20132111.","journal-title":"Lancet"},{"key":"21_CR44","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.1086\/427906","volume":"40","author":"C.A. Benson","year":"2005","unstructured":"Benson CA, Kaplan JE, Masur H, et al.: Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association\/Infectious Diseases Society of America. Clin Infect Dis 2005, 40:S151.","journal-title":"Clin Infect Dis"},{"key":"21_CR45","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1086\/427295","volume":"40","author":"L.M. Mofenson","year":"2005","unstructured":"Mofenson LM, Oleske J, Serchuck L, et al.: Treating opportunistic infections among HIV-exposed and infected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. Clin Infect Dis 2005, 40:S20.","journal-title":"Clin Infect Dis"},{"key":"21_CR46","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1086\/430608","volume":"41","author":"S.S. Long","year":"2005","unstructured":"Long SS: Capsules, clones, and curious events: pneumococcus under fire from polysaccharide conjugate vaccine [editorial]. Clin Infect Dis 2005, 41:30\u201334.","journal-title":"Clin Infect Dis"},{"key":"21_CR47","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1056\/NEJMra010462","volume":"345","author":"G.S. Giebink","year":"2001","unstructured":"Giebink GS: The prevention of pneumococcal disease in children. N Engl J Med 2001, 345:1177\u20131183.","journal-title":"N Engl J Med"},{"key":"21_CR48","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1086\/429833","volume":"40","author":"B. Greenwood","year":"2005","unstructured":"Greenwood B: Interpreting vaccine efficacy [editorial]. Clin Infect Dis 2005, 40:1519\u2013520.","journal-title":"Clin Infect Dis"},{"key":"21_CR49","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1056\/NEJMoa051642","volume":"354","author":"M.H. Kyaw","year":"2006","unstructured":"Kyaw MH, Lynfield R, Schaffner W, et al.: Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006, 354:1455\u20131463.","journal-title":"N Engl J Med"},{"key":"21_CR50","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(03)14022-6","volume":"362","author":"K.L. O\u2019Brien","year":"2003","unstructured":"O\u2019Brien KL, Moulton LH, Reid R, et al.: Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomized trial. Lancet 2003, 362:355\u2013361.","journal-title":"Lancet"},{"key":"21_CR51","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1086\/430604","volume":"41","author":"C.L. Byington","year":"2005","unstructured":"Byington CL, Samore MH, Stoddard GJ, et al.: Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain West: emergence of nonvaccine serogroups. Clin Infect Dis 2005, 41:21\u201329.","journal-title":"Clin Infect Dis"},{"key":"21_CR52","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa022823","volume":"348","author":"C.G. Whitney","year":"2003","unstructured":"Whitney CG, Farley MM, Hadler J, et al.: Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003, 348:1737\u20131746.","journal-title":"N Engl J Med"},{"key":"21_CR53","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1086\/422653","volume":"39","author":"T.R. Talbot","year":"2004","unstructured":"Talbot TR, Poehling KA, Hartert TV, et al.: Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in Tennessee after introduction of the pneumococcal conjugate vaccine. Clin Infect Dis 2004, 39:641\u2013648.","journal-title":"Clin Infect Dis"},{"key":"21_CR54","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1086\/315009","volume":"180","author":"N. Mbelle","year":"1999","unstructured":"Mbelle N, Huebner RE, Wasas AD, et al.: Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J Infect Dis 1999, 180:1171\u20131178.","journal-title":"J Infect Dis"},{"key":"21_CR55","unstructured":"Recommended childhood and adolescent immunization schedule, United States, 2006. MMWR 2006, 54:Q1\u2013Q4."},{"key":"21_CR56","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1056\/NEJMe068038","volume":"354","author":"D.M. Musher","year":"2006","unstructured":"Musher DM: Pneumococcal vaccine\u2014direct and indirect (\u201cherd\u201d) effects [editorial]. N Engl J Med 2006, 354:1522\u20131524.","journal-title":"N Engl J Med"},{"key":"21_CR57","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1086\/425908","volume":"190","author":"N. Porat","year":"2004","unstructured":"Porat N, Arguedas A, Spratt BG, et al.: Emergence of penicillin-nonsusceptible Streptococcus pneumoniae clones expressing serotypes not present in the antipneumococcal conjugate vaccine. J Infect Dis 2004, 190:2154\u20132162.","journal-title":"J Infect Dis"},{"key":"21_CR58","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1086\/345833","volume":"36","author":"M.H. Lebel","year":"2003","unstructured":"Lebel MH, Kellner JD, Ford-Jones EL, et al.: A pharmacoeconomic evaluation of 7-valent pneumococcal conjugate vaccine in Canada. Clin Infect Dis 2003, 36:259\u2013268.","journal-title":"Clin Infect Dis"},{"key":"21_CR59","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1016\/S0140-6736(03)13779-8","volume":"361","author":"R.E. Black","year":"2003","unstructured":"Black RE, Morris SS, Bryce J: Where and why are 10 million children dying every year? Lancet 2003, 361:2226\u20132234.","journal-title":"Lancet"}],"container-title":["Current HIV\/AIDS Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-007-0021-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11904-007-0021-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-007-0021-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,21]],"date-time":"2021-08-21T23:57:33Z","timestamp":1629590253000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11904-007-0021-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["21"],"URL":"https:\/\/doi.org\/10.1007\/s11904-007-0021-x","relation":{},"ISSN":["1548-3568","1548-3576"],"issn-type":[{"value":"1548-3568","type":"print"},{"value":"1548-3576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8]]}}}